Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
argenx SE heads into its October 22 quarterly results with the stock down 6% over the past month and a cluster of insider sales sitting on the tape, yet the lending market sees no meaningful short conviction at all.
The insider activity is the most notable signal this week. The net picture over the past 90 days is unambiguously negative: insiders sold a net 32,589 shares worth roughly EUR 47.7 million in aggregate. The headline transaction was founder and CEO Timothy Van Hauwermeiren selling 20,000 shares at EUR 908 on September 3, a EUR 18.2 million disposal. The General Counsel and Chief Medical Officer followed with sales of EUR 1.1 million and EUR 1.6 million respectively in early September. The remaining transactions were unpriced option exercises, which carry less signal than discretionary open-market sales. None of the recorded sales are flagged as pre-arranged plan trades. The cluster of C-suite sales at prices above EUR 900, against a current price of EUR 838.60, adds context to the month's 6% slide.
The lending market tells a completely different story. Short interest in argenx is negligible by any measure: availability is essentially uncapped, with over 15.6 million shares available to borrow against minimal demand, and borrowing costs have been anchored near 0.70% for weeks, barely above the risk-free floor. The ORTEX short score of 30, ranking in the 84th percentile for low short pressure, reflects that bears have not built any meaningful position against the stock. Utilization peaked at 1.02% in late September and has since drifted back toward 0.5%. This is not a setup where shorts are piling in to exploit the insider selling.
On valuation, argenx trades at 26.7x trailing earnings and 22x EV/EBITDA, with both multiples contracting over the past 30 days. The PE has come in by roughly 2 turns over the month, and EV/EBITDA by 2.6 turns, consistent with a stock that has re-rated lower on price without a corresponding earnings revision. Factor scores paint an encouraging picture on momentum and earnings quality: EPS momentum ranks in the 90th percentile on a 30-day basis and the 81st on 90 days, with an EPS surprise rank of 77. The valuation factor is the obvious drag, ranking in the 27th percentile on EV/EBIT, a reflection of the premium the market still assigns to efgartigimod's multi-indication growth story. Analyst data on file is too dated to carry into this note without misrepresenting the Street's current positioning.
Among the closest correlated peers this week, GMAB bucked the sector drift with a 6.1% weekly gain. VRTX slipped 3.3% and BSLN fell 5.3%, suggesting the pressure on argenx this week is broadly consistent with the immunology and rare-disease cohort rather than stock-specific deterioration.
The prior two earnings prints are worth noting without reading too much into them. The July 2026 results produced a 6.1% one-day gain, which then faded to a net loss of 1.6% over five days. The May 2026 print saw a 2.6% drop on the day before recovering 0.8% over the week. Both moves were modest relative to the stock's historical volatility. With the next print 14 days away, what matters most is whether the commercial trajectory for efgartigimod shows the kind of acceleration that would justify the remaining valuation premium after a month of de-rating, and whether management's own share sales at prices well above current levels become a talking point on the call.
See the live data behind this article on ORTEX.
Open ARGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
